March 16, 2021 10:52 AM EDT

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody

Kyle Blankenship

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

At the two-year mark, Roche’s Evrysdi (risdiplam) either maintained or improved motor function from a one-year check-up in patients aged 2 to 25 with Types …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody

Kyle Blankenship

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

Senior Editor

Editor

Sign up to read this article for free.

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody